focus -WSS

focus

author：leisure time 2025-09-28 23:49:54 - browse：91435

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

WSS

Private equity deals in Medicare Advantage declines

Industry veterans launch new biotech VC with $310M

Medicare Advantage proposed rates disappoint insurers

Why rehabilitation engineers need to center patients in their research

Biden report: The neurospychology of memory and aging

Senators start work on Medicare physician payment reform

leisure time

focus

explore

How one medical school became remarkably diverse

The Readout: Gilead, Bernie Sanders, and other pharma news

Guidelines to prevent youth baseball injuries need more muscle

Cell therapy fails to slow type 1 diabetes, but safety is established

In age of alternative facts, a scholarly course on calling out crap

Bird flu in milk supply is likely coming from asymptomatic cows

FDA approval of Sarepta Duchenne genetic therapy gives me hope

More tobacco lobbyists active in statehouses

Guidelines to prevent youth baseball injuries need more muscle

Vaccine advisory panel ACIP left half staffed by HHS

hotspot

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Vaccine advisory panel ACIP left half staffed by HHS

To avoid data mishandling cases, universities eye AI and other tools

The Readout: Gilead, Bernie Sanders, and other pharma news

Dogs on Prozac: What pet anti

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

focus

entertainment

hotspot

Wikipedia